DM Clinical Research Launches Its First Advisory Board to Drive Innovation and Growth

In a significant move towards enhancing its operational strategies, DM Clinical Research has officially announced the formation of its inaugural Advisory Board. Headquartered in Houston, Texas, DM Clinical Research is a prominent multi-therapeutic site network that has been making waves in the clinical trial sector since its establishment in 2006. The newly formed Advisory Board consists of highly regarded leaders in clinical research and healthcare, who will offer strategic guidance to DM Clinical's Executive Leadership Team.

As articulated by CEO Mohammad Millwala, the company is on the cusp of an exciting growth trajectory. Millwala expressed his honor in collaborating with such distinguished figures, emphasizing the critical role the Advisory Board will play in addressing growth priorities and operational excellence. He stated, "As a privately held, founder-led organization, our leadership team is accountable for executing a data-driven expansion plan. The Advisory Board's expertise and networks will help us scale responsibly while advancing patient-centric research."

The membership of the Advisory Board includes industry veterans such as Kushal Gohil, Senior Vice President of Global Project Leadership and Launch Excellence at Parexel. Gohil brings years of experience within the Contract Research Organization (CRO) sector. His comprehensive expertise spans numerous facets of the industry, including operations, corporate strategy, corporate development, sales operations, brand management, market research, and account management. Gohil's extensive academic background, with an MBA from MIT Sloan and master's degrees in Drug Development and Marketing from the University of Cincinnati, solidifies his position as a thought leader in the field.

Gohil expressed his enthusiasm about joining the Advisory Board, stating, "Patients and sites are at the heart of every clinical trial, and I'm excited to help advance DM Clinical's mission to deliver innovative solutions that put patients first, empower sites, and drive meaningful progress in clinical research."

DM Clinical Research boasts an integrated national network of clinical trial sites, now comprising over 35 research centers and physician practice embedded sites. Its diverse portfolio caters to a variety of therapeutic areas, supported by a commitment to advancing medical knowledge through rigorous and responsible clinical trials. The company has also garnered several accolades, including the 2024 Society for Clinical Research Sites Site Spark Award and the 2023 Best Clinical Trial Network Award by World Vaccine Congress.

Partnering with well-established global pharmaceutical sponsors, DM Clinical Research is passionate about providing the community access to cutting-edge research opportunities. This research is conducted under the careful medical oversight of skilled physicians and professionals, ensuring high standards of care and ethical practice.

As clinical trials evolve in response to changing healthcare needs, the establishment of a strategic advisory board reflects DM Clinical Research's proactive approach to innovation and patient-centric care. The expertise provided by the board members will be crucial as the organization navigates the complexities of growth and the changing landscape of clinical research.

For individuals and organizations interested in learning more about DM Clinical Research and its initiatives, additional information can be found at dmclinical.com, or by calling (281) 517-0550. As clinical trials become increasingly pivotal in shaping modern healthcare, DM Clinical Research stands ready to lead the way in innovative and ethically conducted research.